1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Lipocine Inc. - Product Pipeline Review - 2015

Lipocine Inc. - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 29 pages

Lipocine Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Lipocine Inc. - Product Pipeline Review - 2015’, provides an overview of the Lipocine Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lipocine Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Lipocine Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Lipocine Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Lipocine Inc.’s pipeline products

Reasons to buy

- Evaluate Lipocine Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Lipocine Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Lipocine Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Lipocine Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lipocine Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Lipocine Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Lipocine Inc. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Lipocine Inc. Snapshot 5
Lipocine Inc. Overview 5
Key Information 5
Key Facts 5
Lipocine Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Lipocine Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Out-Licensed Products 10
Out-Licensed Products/Combination Treatment Modalities 11
Lipocine Inc. - Pipeline Products Glance 12
Lipocine Inc. - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
Lipocine Inc. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Lipocine Inc. - Drug Profiles 15
testosterone undecanoate 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
LPCN-1111 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
hydroxyprogesterone caproate 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Lipocine Inc. - Pipeline Analysis 18
Lipocine Inc. - Pipeline Products by Target 18
Lipocine Inc. - Pipeline Products by Route of Administration 19
Lipocine Inc. - Pipeline Products by Molecule Type 20
Lipocine Inc. - Pipeline Products by Mechanism of Action 21
Lipocine Inc. - Recent Pipeline Updates 22
Lipocine Inc. - Dormant Projects 26
Lipocine Inc. - Locations And Subsidiaries 27
Head Office 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 28
Disclaimer 29

List of Tables
Lipocine Inc., Key Information 5
Lipocine Inc., Key Facts 5
Lipocine Inc. - Pipeline by Indication, 2015 7
Lipocine Inc. - Pipeline by Stage of Development, 2015 8
Lipocine Inc. - Monotherapy Products in Pipeline, 2015 9
Lipocine Inc. - Out-Licensed Products in Pipeline, 2015 10
Lipocine Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 11
Lipocine Inc. - Phase III, 2015 12
Lipocine Inc. - Phase II, 2015 13
Lipocine Inc. - Phase I, 2015 14
Lipocine Inc. - Pipeline by Target, 2015 18
Lipocine Inc. - Pipeline by Route of Administration, 2015 19
Lipocine Inc. - Pipeline by Molecule Type, 2015 20
Lipocine Inc. - Pipeline Products by Mechanism of Action, 2015 21
Lipocine Inc. - Recent Pipeline Updates, 2015 22
Lipocine Inc. - Dormant Developmental Projects,2015 26

List of Figures
Lipocine Inc. - Pipeline by Top 10 Indication, 2015 7
Lipocine Inc. - Pipeline by Stage of Development, 2015 8
Lipocine Inc. - Monotherapy Products in Pipeline, 2015 9
Lipocine Inc. - Out-Licensed Products in Pipeline, 2015 10
Lipocine Inc. - Pipeline by Top 10 Target, 2015 18
Lipocine Inc. - Pipeline by Top 10 Route of Administration, 2015 19
Lipocine Inc. - Pipeline by Top 10 Molecule Type, 2015 20
Lipocine Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Pipeline Review, H2 2016

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ...

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Growth Hormone Secretagogue Recepto ...

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H2 2016

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.